-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
HC Wainwright Trims Cardiff Oncology (NASDAQ:CRDF) Target Price to $14.00
HC Wainwright Trims Cardiff Oncology (NASDAQ:CRDF) Target Price to $14.00
Cardiff Oncology (NASDAQ:CRDF – Get Rating) had its target price reduced by HC Wainwright from $22.00 to $14.00 in a report issued on Friday morning, The Fly reports. They currently have a buy rating on the stock.
Several other analysts also recently weighed in on CRDF. Piper Sandler dropped their target price on shares of Cardiff Oncology from $7.00 to $5.00 and set an overweight rating for the company in a report on Tuesday, September 13th. Robert W. Baird dropped their price target on shares of Cardiff Oncology from $9.00 to $6.00 and set an outperform rating for the company in a research note on Monday, August 29th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of Buy and a consensus price target of $9.75.
Get Cardiff Oncology alerts:Cardiff Oncology Stock Performance
CRDF stock opened at $1.73 on Friday. The firm has a market cap of $74.92 million, a PE ratio of -1.94 and a beta of 1.38. The firm's 50 day moving average price is $2.51 and its 200-day moving average price is $2.13. Cardiff Oncology has a one year low of $1.13 and a one year high of $7.63.
Cardiff Oncology (NASDAQ:CRDF – Get Rating) last posted its earnings results on Thursday, August 4th. The company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.01. Cardiff Oncology had a negative net margin of 9,841.41% and a negative return on equity of 28.82%. The firm had revenue of $0.09 million during the quarter, compared to the consensus estimate of $0.08 million. Equities research analysts predict that Cardiff Oncology will post -1.04 EPS for the current fiscal year.Insider Buying and Selling
In other news, CFO James E. Levine bought 30,000 shares of the stock in a transaction that occurred on Friday, September 16th. The stock was purchased at an average price of $1.56 per share, for a total transaction of $46,800.00. Following the completion of the purchase, the chief financial officer now owns 60,000 shares in the company, valued at approximately $93,600. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 3.50% of the company's stock.
Hedge Funds Weigh In On Cardiff Oncology
A number of institutional investors and hedge funds have recently modified their holdings of CRDF. Quantbot Technologies LP purchased a new stake in Cardiff Oncology in the first quarter valued at $28,000. LPL Financial LLC lifted its position in Cardiff Oncology by 17.9% in the second quarter. LPL Financial LLC now owns 26,384 shares of the company's stock valued at $58,000 after acquiring an additional 3,998 shares during the last quarter. XTX Topco Ltd purchased a new stake in Cardiff Oncology in the first quarter valued at $62,000. Price T Rowe Associates Inc. MD lifted its position in Cardiff Oncology by 69.9% in the second quarter. Price T Rowe Associates Inc. MD now owns 36,500 shares of the company's stock valued at $80,000 after acquiring an additional 15,020 shares during the last quarter. Finally, GSA Capital Partners LLP purchased a new stake in Cardiff Oncology in the fourth quarter valued at $93,000. Institutional investors and hedge funds own 20.70% of the company's stock.
Cardiff Oncology Company Profile
(Get Rating)
Cardiff Oncology, Inc, a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.
Featured Articles
- Get a free copy of the StockNews.com research report on Cardiff Oncology (CRDF)
- Oracle's Short-Term Pain Could Be Your Long-Term Gain
- Lucid is Looking Like a Clear EV Winner
- Still Lovin' It: Investors Keep Visiting McDonald's
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
Receive News & Ratings for Cardiff Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiff Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
Cardiff Oncology (NASDAQ:CRDF – Get Rating) had its target price reduced by HC Wainwright from $22.00 to $14.00 in a report issued on Friday morning, The Fly reports. They currently have a buy rating on the stock.
據The Fly報道,在週五上午發佈的一份報告中,加的夫腫瘤公司(納斯達克代碼:CRDF-GET評級)被HC Wainwright公司的目標價從22.00美元下調至14.00美元。他們目前對該股的評級為買入。
Several other analysts also recently weighed in on CRDF. Piper Sandler dropped their target price on shares of Cardiff Oncology from $7.00 to $5.00 and set an overweight rating for the company in a report on Tuesday, September 13th. Robert W. Baird dropped their price target on shares of Cardiff Oncology from $9.00 to $6.00 and set an outperform rating for the company in a research note on Monday, August 29th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of Buy and a consensus price target of $9.75.
其他幾位分析師最近也加入了對CRDF的看法。派珀·桑德勒在9月13日星期二的一份報告中將卡迪夫腫瘤公司的股票目標價從7.00美元下調至5.00美元,併為該公司設定了增持評級。羅伯特·W·貝爾德在8月29日星期一的一份研究報告中將加的夫腫瘤公司的股票目標價從9.00美元下調至6.00美元,併為該公司設定了表現優於大盤的評級。根據MarketBeat.com的數據,五位股票研究分析師對該股的評級為買入,該股的平均評級為買入,共識目標價為9.75美元。
Cardiff Oncology Stock Performance
加的夫腫瘤學股票表現
CRDF stock opened at $1.73 on Friday. The firm has a market cap of $74.92 million, a PE ratio of -1.94 and a beta of 1.38. The firm's 50 day moving average price is $2.51 and its 200-day moving average price is $2.13. Cardiff Oncology has a one year low of $1.13 and a one year high of $7.63.
CRDF股票上週五開盤報1.73美元。該公司市值為7492萬美元,市盈率為-1.94,貝塔係數為1.38。該公司的50日移動均線價格為2.51美元,200日移動均線價格為2.13美元。加的夫腫瘤學的一年低點為1.13美元,一年高位為7.63美元。
Insider Buying and Selling
內幕買賣
In other news, CFO James E. Levine bought 30,000 shares of the stock in a transaction that occurred on Friday, September 16th. The stock was purchased at an average price of $1.56 per share, for a total transaction of $46,800.00. Following the completion of the purchase, the chief financial officer now owns 60,000 shares in the company, valued at approximately $93,600. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 3.50% of the company's stock.
在其他新聞方面,首席財務官詹姆斯·E·萊文在9月16日星期五的一筆交易中購買了30,000股該公司股票。股票是以每股1.56美元的平均價格購買的,總交易額為46,800.00美元。收購完成後,首席財務官現在擁有該公司60,000股股份,價值約93,600美元。此次收購是在提交給美國證券交易委員會的一份法律文件中披露的,用户可以通過以下鏈接訪問該文件。內部人士持有該公司3.50%的股份。
Hedge Funds Weigh In On Cardiff Oncology
對衝基金對卡迪夫腫瘤學的看法
A number of institutional investors and hedge funds have recently modified their holdings of CRDF. Quantbot Technologies LP purchased a new stake in Cardiff Oncology in the first quarter valued at $28,000. LPL Financial LLC lifted its position in Cardiff Oncology by 17.9% in the second quarter. LPL Financial LLC now owns 26,384 shares of the company's stock valued at $58,000 after acquiring an additional 3,998 shares during the last quarter. XTX Topco Ltd purchased a new stake in Cardiff Oncology in the first quarter valued at $62,000. Price T Rowe Associates Inc. MD lifted its position in Cardiff Oncology by 69.9% in the second quarter. Price T Rowe Associates Inc. MD now owns 36,500 shares of the company's stock valued at $80,000 after acquiring an additional 15,020 shares during the last quarter. Finally, GSA Capital Partners LLP purchased a new stake in Cardiff Oncology in the fourth quarter valued at $93,000. Institutional investors and hedge funds own 20.70% of the company's stock.
一些機構投資者和對衝基金最近調整了對CRDF的持股。Quantbot Technologies LP在第一季度購買了加的夫腫瘤公司的新股份,價值2.8萬美元。LPL Financial LLC在第二季度將其在加的夫腫瘤學的地位提高了17.9%。LPL Financial LLC現在擁有26,384股該公司的股票,價值58,000美元,在上個季度額外購買了3,998股。XTX Topco Ltd在第一季度收購了加的夫腫瘤學公司的新股份,價值6.2萬美元。Price T Rowe Associates Inc.MD在第二季度將其在加的夫腫瘤學的地位提高了69.9%。Price T Rowe Associates Inc.MD現在擁有36,500股該公司股票,價值80,000美元,此前該公司在上個季度又收購了15,020股。最後,GSA Capital Partners LLP在第四季度購買了加的夫腫瘤公司的新股份,價值93,000美元。機構投資者和對衝基金持有該公司20.70%的股票。
Cardiff Oncology Company Profile
加的夫腫瘤學公司簡介
(Get Rating)
(獲取評級)
Cardiff Oncology, Inc, a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.
加的夫腫瘤學公司是一家臨牀階段的腫瘤學公司,在加利福尼亞州為癌症患者開發藥物治療。它的主要候選藥物是onvansertib,一種用於抗癌治療的口服選擇性Polo-like Kinase 1抑制劑;CY140,一種PLK1、PLK2和PLK3的抑制劑,正處於實體腫瘤和白血病的1/2期研究;轉移性結直腸癌,正在進行臨牀試驗;以及trov-054,是FOLFIRI和貝伐單抗的1b/2期藥物。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on Cardiff Oncology (CRDF)
- Oracle's Short-Term Pain Could Be Your Long-Term Gain
- Lucid is Looking Like a Clear EV Winner
- Still Lovin' It: Investors Keep Visiting McDonald's
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
- 免費獲取StockNews.com關於卡迪夫腫瘤學的研究報告(CRDF)
- 甲骨文的短期痛苦可能是你的長期收益
- Lucid看起來像是電動汽車的贏家
- 仍然愛着它:投資者繼續光顧麥當勞
- 聯邦快遞剛剛提供了一個買入機會嗎?
- 自動區重新進入拉力賽模式,新高在望
Receive News & Ratings for Cardiff Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiff Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
接受加的夫腫瘤學日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對加的夫腫瘤學和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧